Pitriyazis Versikolor, Pitriyazis Rozea, Seboreik Dermatit ve Herpes Zoster’in Yaş, Cinsiyet, Mevsim ve Aylara Göre Dağılımının Karşılaştırılması

Yıl 2019, , 169 - 173, 30.09.2019

Mahizer Yaldız

https://doi.org/10.34087/cbusbed.476521

Öz

Objective: There are several studies reporting that pitriasis versicolor (PV), pitriasis rosea(PR), seborrheic dermatitis(SD) and herpes zoster(HZ) have been affected by seasonal changes. In our study, we aimed to determine the relation ship of these diseases with age, gender, seasons and months.
Methods: A total of 4946 patients diagnosed with PV, PR, SD or HZ who applied to our dermatology clinic between the dates, November 2015 and November 2018 were retrospectively evaluated from the automation system.
Results: Of 4946 patients included in the study, 2833 were female (57.27%) and 2113 (42.73%) were male.We determined that PV was seen at the highest rate in summer, PR in Spring, HZ in fall and SD in fall and summer. Our prevalence rates were calculated as PV: 1.08%, PR: 0.5%, SD: 0.6% and HZ: 0.01%.
Conclusion: Although the seasonal effects of the existing diseases are determined, these findings should be supported by multicentre, prospective, large case studies.

Anahtar Kelimeler

Pityriasis Versicolor, Pityriasis Rosea, Seborrheic Dermatitis, Herpes Zoster

Pitriyazis Versikolor, Pitriyazis Rozea, Seboreik Dermatit ve Herpes Zoster’in Yaş, Cinsiyet, Mevsim ve Aylara Göre Dağılımının Karşılaştırılması

Öz

Amaç:
 Pitriazis Versicolor(PV), Pitriazis Rozea(PR),
Seboreik Dermatit(SD) ve Herpes Zoster’(HZ)in mevsimsel değişikliklerden etkilendiği  bildiren birkaç çalışma mevcuttur.  Çalışmamızda bu hastalıkların yaş, cinsiyet,
mevsim ve aylar ile olan ilişkisini saptamayı amaçladık

Gereç
ve yöntemler: Kasım 2015 - kasım 2018 tarihleri arasında dermatoloji
polikliniğimize başvuran PV, PR, SD veya HZ tanısı alan toplam 4946 hasta otomasyon
sisteminden  retrospektif olarak
değerlendirildi.

Bulgular:
Çalışmaya dahil edilen 4946 hastanın, 2833’si kadın (%57,27), 2113’u erkek
(%42,73) idi. PV yaz, PR ilkbahar, HZ sonbahar ve SD sonbahar ve yaz  aylarında en yüksek oranda görüldüğünü tespit
ettik. Prevalans oranlarımız PV:%1,08, PR: %0,5, SD: %0,6 ve  HZ: %0,01 olarak hesaplandı.

Sonuç:
Dermagrafik dağılımın, coğrafi şartların ve iklimin değişken olduğu ülkemizde
hasta sayısı olarak en büyük seriye sahip olan çalışmamız literatüre
destekleyecek bir kaynak olduğunu düşünmekteyiz.

Anahtar Kelimeler

Pitriazis Versicolor, Pitriazis Rozea, Seboreik Dermatit, herpes zoster

Kaynakça

• 1. Burke RC. Tineaversicolor: susceptibility factors and experimental infection in human beings. J InvestDermatol. 1961; 36: 389 402.
• 2. Faergemann J, Bernander S. Tinea versicolor and Pityrospor umorbiculare: a mycological investigation. Sabouraudia. 1979; 17: 171–179.
• 3. Fitzpatrick TB: Dermatology in general medicine. (McGraw-Hill, New York). 2003; 445-450.
• 4. Saçar T, Saçar H. Comparison of the Distributions of Seborrheic Dermatitis, Herpes Zoster and Pityriasis Rosea According to Seasons. Türkderm. 2010; 44: 65-8.
• 5. Chuang TY, Ilstrup DM, Perry HO, Kurland LT: Pityriasis rosea in Rochester, Minnesota, 1969 to1978. J Am Acad Dermatol. 1982;7: 80–89.
• 6. Stefanaki, I. ve Katsambas, A. Therapeutic update on sebborheic dermatitis. Skin TherLett. 2010;15(5): 1-4.
• 7. Donald H. Gilden, Randall J. Cohrs, Ravi Mahalingam. Viral Immunology. 2003;16:243-58.
• 8. Gershon AA: Varicella-ZosterVirusInfections. Pediatr Rev. 2008;29:5-11.
• 9. CrespoVE,Martos AO, Casańo AV, Fajardo FS.Malassezia globosaas the causative agent of pityriasis versicolor. British journal of Dermatology. 2000; 143: 799-803.
• 10. Roberts SOB. Pityriasis versicolor: a clinical and mycological investigation. Br J Dermatol. 1969;81: 315–311.
• 11. Abdul Razack EM, Thambiah AS. A clinical study of pityriasis versicolor in Madras. Sabouraudia. 1977; 14: 129–148.
• 12. Watanabe T, Kawamura T, Jacob SE. Pityriasis Rosea is Associated with Systemic Active Infection with Both Human Herpes virus-7 and Human Herpes virus. J InvestDermatol. 2002;119:793-7.
• 13. Harman M, Aytekin S, Akdeniz S, Inaloz HS. An epidemiological study of pityriasis rosea in the Eastern Anatolia. Eur J Epidemiol. 1998;14:495-7.
• 14. Başkan EM,Turan H,Ercan İ,Yazıcı S.,Özkaya G, Sarıcaoğlu H. Pitriyazis Rozea Olgularında Demografik Ozellikler ve iklimsel Faktorlerin icelenmesi. Turkderm. 2011; 45: 97-9.
• 15. Bjornberg A, Hellgren L. Pityriasis rosea. A statistical, clinical, and laboratory investigation of 826 patients and matched healthy controls. Acta Derm Venereol Suppl (Stockh). 1962;42:1-68.
• 16. Tay YK, Goh CL. One-year review of pityriasis rosea at the National Skin Centre, Singapore. Ann Acad Med Singapore. 1999;28:829-31.
• 17. Olumide Y: Pityriasis rosea in Lagos. Int J Dermatol. 1987;26:234-6.
• 18. Bjornberg A, Tegner E. Pityriasis rosea. In Freedberg IM, Eisen AZ, Wolff K(eds) Fitzpatrick's Dermatology in General Medicine, 5th edition, Mc Graw Hill NY, 1999:541-6.
• 19. Sahin MT, Ermertcan AT, Kapulu N, Öztürkcan S. Son 5 yılda pitiriyazis rozea tanısı alan hastaların retrospektif değerlendirilmesi. ADÜ Tıp Fakültesi Dergisi. 2002;3:21-3.
• 20. Tüzün Y, Keskin S: Pitiriyazis Rozea. Dermatose. 2005;4:202-6.
• 21. Tamer E,Ilhan MN, Polat M, Lenk N, Allı N. Prevalence of skin diseases among pediatric patients in Turkey. J Dermatol. 2008;35:413-8.
• 22. Chuh AAT, Lee A, Molinari N: Case Clustering in Pityriasis Rosea. Arch Dermatol. 2003;139:489-93.
• 23. Ahmed MA: Pityriasis rosea in the Sudan. Int J Dermatol. 1986;25:184-5.
• 24. Cheong WK, Wong KS. An epidemiological study of pityriasis rosea in middle road hospital. Sing Med J. 1989;30:60-2.
• 25. Jacyk WK: Pityriasis rosea in Nigerians. Int J Dermatol. 1980;19:397-9.
• 26. Hancox JG, Sheridan SC, Feldman SR, Fleischer AB Jr. Seasonal variation of dermatologic disease in the USA: a study of Office visits from 1990 to 1998. Int J Dermatol. 2004;43:6-11.
• 27. Maietta G, Rongioletti F, Rebora A. Seborrheic dermatitis and daylight. ActaDermVenereol. 1991;71:538-9.
• 28. Inalöz HS, Kırtak N: Seboreik dermatitin patogenez ve tedavisi. T Klin Tıp Bilimleri. 2002;22:239-44.
• 29. Whitley RJ. Varicella-zostervirusinfections. In: Kasper LD, Braunwald E,Fauci SA, Hauser LS, Longo LD, Jameson LJ(eds). Harrison’s PrinciplesInternal Medicine.16th ed. United States of America, McGraw-Hill, 2005; 1042-45.
• 30. Zak-Prelich M, Borkowski JL, Alexander F, Norval M. The role ofsolar ultravioletirradiation in zoster. Epidemiol Infect. 2002;129:593-7.
• 31. Lin YH, Huang LM, Chang IS. Disease burden and epidemiology of herpes zoster in pre-vaccine Taiwan. Vaccine. 2010;28:1217-20.
• 32. Weinberg JM. Herpes zoster: epidemiology, natural history, and common complications. J Am Acad Dermatol. 2007;57:130-5.
• 33. Çelik Ü, Alhan E, Aksaray N. Malignensili Çocuklarda Varisella-Zoster Virüs Enfeksiyonu. Çocuk Enf Derg. 2008;3:105-8.
• 34. Socan M, Blako M. Surveillance of varicella and herpes zoster in Slovenia, 1996-2005. Euro surveillance. 2007:13-16.
• 35. Miller ER, Kelly HA. Varicella infection-Evidence for peak activity in summer months. Journal of Infection. 2008;56:360-5.
• 36. Glynn C, Crockford C, Gavaghan D, Cardno P, Price D, Miller J. Epidemiology of shingles. Journal of theRoyalSociety of Medicine.1990;83:617-9.
• 37. Toyama N, Shiraki K. Society of the Miyazaki Prefecture Dermatologists: Epidemiology of herpes zoster and its relationship to varicella in Japan: A 10-year survey of 48,388 herpes zoster cases in Miyazaki prefecture. J Med Virol. 2009;81:2053-8.